Oxford Biomedica PLC Oxford Biomedica upgrades financial guidance (9172Y)
18 May 2021 - 4:00PM
UK Regulatory
TIDMOXB
RNS Number : 9172Y
Oxford Biomedica PLC
18 May 2021
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of
domestic law by virtue of the European Union (Withdrawal) Act
2018). Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to
be in the public domain.
Oxford Biomedica upgrades financial guidance for supply
agreement with AstraZeneca for manufacture of COVID-19 Vaccine
Oxford, UK - 18 May, 2021: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, announced today an update on the 18 month supply
agreement signed with AstraZeneca UK Ltd ("AstraZeneca") in
September 2020.
Following successful manufacture of large-scale batches of
AstraZeneca's COVID-19 Vaccine, AstraZeneca has today committed to
an increase in the number of batches required from Oxford Biomedica
in the second half of 2021. As a result of this, the Group is
raising revenue guidance for expected cumulative revenues from
AstraZeneca by the end of 2021 from in excess of GBP50 million to
in excess of GBP100 million, and as a result expects significant
growth in Group Operating EBITDA in the year ending 2021.
As previously guided, Oxford Biomedica does not expect the
commitment to AstraZeneca for vaccine production to have any impact
on the Group's current partnerships or ability to secure and
support additional new partnerships in the cell and gene therapy
field.
Background to the agreement with AstraZeneca
Oxford Biomedica announced an 18 month supply agreement in
September 2020 under a three year Master Supply and Development
Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca")
for large-scale commercial manufacture of the adenovirus
vector-based COVID-19 vaccine, AZD1222. (see LINK).
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
"Everyone involved with production of the COVID-19 Vaccine can be
truly proud of their achievement in manufacturing batches of
vaccine from our Oxbox manufacturing facility. We are delighted to
be a key supplier of the vaccine and the Group is proud to be part
of this world-leading vaccination project that is saving many
lives."
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR T: +44 (0)1865 954 161 / E: ir@oxb.com
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, cell
and gene therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders and liver diseases. The
Group has also entered into a number of partnerships, including
with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Additionally the
group has signed a 3 year master supply and development agreement
with AstraZeneca for large-scale manufacturing of the adenoviral
based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across
several locations in Oxfordshire, UK and employs more than 670
people. Further information is available at www.oxb.com
The person who arranged for the release of this announcement on
behalf of Oxford Biomedica plc was John Dawson, Chief Executive
Officer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFDLLFFELLBBV
(END) Dow Jones Newswires
May 18, 2021 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024